CASE REPORT
Fibrolamellar hepatocellular carcinoma: Case report
 
More details
Hide details
1
Department of Oncology, JSC ‘Astana Medical University,’ Nur-Sultan, Republic of Kazakhstan
2
Chair of Pathological Anatomy, Multidisciplinary Medical Center, Nur-Sultan, Republic of Kazakhstan
CORRESPONDING AUTHOR
Ivan I. Shtefanov   

Department of Oncology, JSC ‘Astana Medical University,’ 010000, 49A Beybitshilik Str., Nur-Sultan, Republic of Kazakhstan. Tel.: +77172539424.
Submission date: 2020-04-09
Final revision date: 2020-05-22
Acceptance date: 2020-05-23
Online publication date: 2020-09-07
 
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Fibrolamellar carcinoma is a rare primary hepatic malignant tumour, which was first described as a pathological variant of hepatocellular carcinoma.

Aim:
The aim of the paper is to discuss the case report of surgical treatment of a multicentric form of presumably fibrolamellar carcinoma significantly exceeding the Barcelona Clinic Liver Cancer staging system criteria, although tumour size and multi-organ lesions are not a contraindication to resection.

Case study:
This case report is an original one because the surgical intervention was performed on a patient with a multicentric fibrolamellar hepatocellular carcinoma with the initial foci of 16.0 × 12.0 × 9.0 cm and 10.5 × 8.7 × 7.5 cm.

Results and discussion:
The surgical intervention (right hemihepatectomy, lymphatic dissection D2) was performed as an independent treatment without prior chemotherapy.

Conclusions:
The surgical treatment occurred 5 years ago, and at the time of writing there has been no relapse and no sign of progression.

CONFLICT OF INTEREST
None declared.
FUNDING
None declared.
 
REFERENCES (15)
1.
Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of the liver in infancy and childhood. AMA Am J Dis Child. 1956;91(2):168–186. https://doi.org/10.1001/archpe....
 
2.
Haque W, Verma V, Naik N, Butler EB. Metaplastic breast cancer: practice patterns, outcomes, and the role of radiotherapy. Ann Surg Oncol. 2018;25(4):928–936. https://doi.org/10.1245/s10434....
 
3.
Drekolias D, Mamounas EP. Metaplastic breast carcinoma: current therapeutic approaches and novel targeted therapies. Breast J. 2019;25(6):1192–1197. https://doi.org/10.1111/tbj.13....
 
4.
Kumar M, Kumar M, Nigam JS, Khanna P, Arora A. Metaplastic carcinoma of the breast – Case report and review of literature. Int J Surg Open. 2020;24:43–46. https://doi.org/10.1016/j.ijso....
 
5.
Yamashita Y, Kitano M, Ashida R. Value of endoscopy for early diagnosis of pancreatic carcinoma. Dig Endosc. 2020;32(1):27–36. https://doi.org/10.1111/den.13....
 
6.
Hori A, Ohira R, Nakamura T, et al. Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma. Br J Radiol. 2020;93(1110)20190407. https://doi.org/10.1259/bjr.20....
 
7.
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. https://doi.org/10.1055/s-2007....
 
8.
Chelimeda S, Bejarano T, Lowe R, Soliman M, Zhao Q, Hartshorn KL. Long-term survival after resection of lung metastases from hepatocellular cancer: report of a case and review of the literature. Case Rep Oncol. 2016;9(3):559–564. https://dx.doi.org/10.1159%2F0....
 
9.
Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30–60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol. 2014;37(1):165–175. https://dx.doi.org/10.1007%2Fs....
 
10.
Cai Q, Jiang J, Jin R, Jin G, Jia N. The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma. Oncol Lett. 2020;19(1):159–166. https://dx.doi.org/10.3892%2Fo....
 
11.
Bazin IS, Borisov VI, Breder VV, Byakhov MYu, Virshke ER. Clinical recommendations. Cancer of the liver (hepatocellular). Moscow: Association of Oncologists of Russia; 2018 [in Russian].
 
12.
Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res Treat. 2015;47(4):853–861. https://dx.doi.org/10.4143%2Fc....
 
13.
Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. https://doi.org/10.1056/nejmoa....
 
14.
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354. https://doi.org/10.1016/S1470-....
 
15.
Tan N, Liu Q, Liu X, et al. Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis. Histopathol. 2016;68(2):221–229. https://doi.org/10.1111/his.12....